Skip to content
Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Get the podcast

Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid

The Audio Journal of Oncology
Susan O’Brien

Susan O’Brien

SUSAN O’BRIEN, MD Anderson Cancer Center, HoustonFor patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy.Susan O’Brienpresented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.

LISTEN

Tags

cancerchemotherapyhematologicleukemiapatientpodcastpodcastingpresentedrefractoryreportreportstrial

Next in ASH 2007

All 11 interviews

Interview 6 of 11

Live Report from ASH:<br />Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Live Report from ASH:<br />Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows that dasatinib is giving durable responses in patients with chronic phase

10 December 2007

Related Episodes

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min